GeneDx Holdings
About: GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Employees: 1,000
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
344% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 18
126% more capital invested
Capital invested by funds: $799M [Q3] → $1.81B (+$1.01B) [Q4]
109% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 33
94% more call options, than puts
Call options by funds: $18.6M | Put options by funds: $9.6M
67% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 10 (+4) [Q4]
44% more funds holding
Funds holding: 136 [Q3] → 196 (+60) [Q4]
15.59% more ownership
Funds ownership: 69.91% [Q3] → 85.51% (+15.59%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Goldman Sachs Matthew Sykes 43% 1-year accuracy 15 / 35 met price target | 20%upside $80 | Neutral Maintained | 19 Feb 2025 |
Financial journalist opinion
Based on 12 articles about WGS published over the past 30 days
